Financial Performance - The group's revenue increased by approximately RMB 171.5 million or 20.9% to approximately RMB 992.0 million for the year ended December 31, 2022[2]. - Gross profit rose by approximately RMB 143.2 million or 24.8% to approximately RMB 720.9 million compared to the previous year[2]. - EBITDA increased by approximately RMB 143.1 million or 50.8% to approximately RMB 424.9 million for the year ended December 31, 2022[2]. - Profit attributable to equity holders increased by approximately RMB 93.6 million or 49.9% to approximately RMB 281.2 million[2]. - Total comprehensive income for the year was RMB 289.1 million, compared to RMB 181.4 million in the previous year[6]. - The group's profit before tax reached RMB 281,218,000 in 2022, up from RMB 187,643,000 in 2021, representing a growth of 49.9%[28]. - The net profit for the year ended December 31, 2022, was approximately RMB 281.2 million, an increase of about RMB 93.6 million or 49.9% compared to RMB 187.6 million for the year ended December 31, 2021[66]. Revenue Breakdown - Revenue from external customers in mainland China for 2022 was RMB 984,383 thousand, an increase from RMB 817,130 thousand in 2021, representing a growth of approximately 20.5%[17]. - Total revenue for 2022 was RMB 992,014 thousand, compared to RMB 820,543 thousand in 2021, indicating a year-over-year increase of about 20.9%[21]. - Revenue from a major customer (Customer A) accounted for RMB 101,466 thousand in 2022, up from RMB 95,890 thousand in 2021, which is an increase of approximately 5.5%[19]. - Revenue from the sales of Jin Sang Zi throat lozenges (OTC) was approximately RMB 904.6 million, an increase of approximately RMB 165.4 million or 22.4% compared to RMB 739.2 million for the previous year[55]. Assets and Liabilities - Current liabilities totaled RMB 734.6 million, an increase from RMB 579.2 million in the previous year[7]. - Total assets less current liabilities amounted to RMB 1,564.7 million, up from RMB 1,374.0 million in the previous year[10]. - Cash and cash equivalents increased to RMB 895.5 million from RMB 722.8 million in the previous year[9]. - The company's total equity attributable to equity holders increased to RMB 1,539.1 million from RMB 1,365.1 million[11]. - Trade receivables increased to RMB 620,338,000 in 2022 from RMB 417,179,000 in 2021, reflecting a growth of 48.6%[29]. - The aging analysis of trade receivables shows that RMB 23,586,000 was within three months, up from RMB 20,771,000 in 2021[31]. - Trade payables rose to RMB 25,313,000 in 2022, compared to RMB 21,829,000 in 2021, marking an increase of 15.3%[32]. - The group had bank loans repayable within one year amounting to RMB 272,586,000 in 2022, an increase from RMB 234,597,000 in 2021[35]. Expenses and Costs - The total income tax expense for 2022 was RMB 94,775,000, compared to RMB 49,204,000 in 2021, indicating an increase of 92.5%[25]. - The financial costs for 2022 amounted to RMB 10,294,000, an increase of 29.0% from RMB 7,975,000 in 2021[27]. - The company's sales and distribution expenses were approximately RMB 279.0 million, an increase of approximately RMB 17.4 million or 6.7% compared to RMB 261.6 million for the previous year[61]. - The employee costs for the year ended December 31, 2022, were approximately RMB 80.4 million, compared to RMB 79.4 million for the same period in 2021[70]. Dividends - The board proposed a final dividend of HKD 0.36 per share, subject to approval at the upcoming annual general meeting[2]. - The proposed final dividend for 2022 is HKD 0.36 per share, which is double the HKD 0.18 per share proposed for 2021, totaling RMB 237,743,000 compared to RMB 108,802,000[26]. Product Development and Market Presence - The flagship product, Jin Sang Zi Throat Lozenges (OTC), accounted for approximately 91.2% of the total revenue for the year ended December 31, 2022[41]. - Jin Sang Zi Throat Treasure series products contributed about 8.2% to the total revenue for the year ended December 31, 2022[42]. - Other products, including Ginkgo Biloba tablets, represented approximately 0.6% of the total revenue for the year ended December 31, 2022[43]. - The company launched a new product, Jin Sang Zi Intestinal Treasure, in June 2022, which is a proprietary prebiotic aimed at enhancing gut health[44]. - The company aims to improve the health of Chinese consumers with its newly developed active probiotics, which have received six patents[44]. - The company’s sales revenue showed significant improvement in 2022, attributed to the recognition of its products in the treatment of throat symptoms related to COVID-19[40]. - As of December 31, 2022, the company has exported its products to 22 countries and regions, with new additions including France, Spain, the Netherlands, Italy, and Ireland in 2022, and Luxembourg, Croatia, and Estonia in early 2023[47]. - The distribution network covers all provinces, autonomous regions, and municipalities in China, with significant revenue derived from sales to distributors as of December 31, 2022[48]. - The company has established a presence in 53 countries and regions globally, including the US, Canada, Japan, and Australia, with the OTC product gaining registration in Malaysia, set to enter mainstream hospitals and clinics in Q2 2023[49]. Corporate Governance and Compliance - The company has adopted a corporate governance code to ensure shareholder rights and enhance corporate value and accountability[79]. - All directors have complied with the standard code regarding securities trading for the year ended December 31, 2022[80]. - The audit committee reviewed the accounting principles and policies, as well as the audited consolidated financial statements for the year ended December 31, 2022, and found the existing risk management and internal control systems to be effective and adequate[81]. - No purchase, sale, or redemption of the company's listed securities occurred during the year ended December 31, 2022[81]. - The annual report for the year ended December 31, 2022, will be sent to shareholders and published on the stock exchange and the company's website[81].
金嗓子(06896) - 2022 - 年度业绩